Saving lives with fewer practitioners
These changes challenge how pharmaceutical brands engage patients and healthcare providers. Digital health platforms, mobile apps, and AI-driven solutions are not just opportunities for innovation—they are essential for staying competitive in a landscape where healthcare demand is outpacing traditional models.
And that’s just the commercial side. On the human, patient side, the opportunity for timely intervention and saving lives is compelling against a backdrop of steadily fewer practitioners in proportion to an ageing population.
What credentials do we have when writing about such topics? JOURNEY's leadership team has been working with Pharmaceutical and Medical Device companies for over 25 years, leading international change programmes in Europe, North America, and the Middle East.
Much change is happening even in a relatively technologically conservative industry like healthcare. Here are three ways digital trends drive significant change and outcomes for patients, healthcare providers, and pharma brands.
mHealth is changing everything
Digital health platforms fundamentally change how patients interact with healthcare providers and pharmaceutical companies. In the Asia Pacific region, mobile health apps (mHealth) are increasingly being adopted at a seemingly eye-watering speed, driven in part by the pandemic. In October 2020, a GMO study found that respondents from 30% (Japan) to 100% (Malaysia) reported using Health apps. Today, patients have many mHealth apps to track their health, access healthcare information, and communicate with providers.
This shift is creating a more personalised healthcare experience, improving adherence to treatment and engagement with healthcare systems.
AI and Personalisation: shaping patient care
AI in healthcare is becoming indispensable, particularly in personalised medicine. The global AI in Healthcare market size was valued at USD 20.9 billion in 2024 and is estimated to reach USD 148.4 billion by 2029, growing at a compound annual growth rate (CAGR) of 48.1% between 2024 and 2029, as patients and healthcare providers seek more tailored healthcare solutions.
AI-driven tools allow pharma companies to analyse patient data, predict health outcomes, and personalise treatment plans based on individual needs.
It’s strange to say about technology, but it’s hard to read about Lunit AI without feeling emotional. Based in South Korea, Lunit’s AI technology improves the accuracy of cancer diagnoses at a time when radiologists and associated services are under strain. The Cancer Registry of Norway and Odense University Hospital in Denmark just conducted a study and it found that Lunit AI predicts breast cancer risk up to 6 Years in advance, whilst reducing the workload of radiologists.
Build long term loyalty
Digital health tools help pharmaceutical brands reach new patients and create opportunities for long-term loyalty. A systematic review and meta-analysis by Peng et al. (2020) found that mobile apps significantly improved patient adherence to medication for chronic diseases. The same study reported that in those studies where user app acceptability was measured, 91.7% of patients were satisfied with all aspects of the apps.
By offering patients digital platforms to track their treatments, communicate with healthcare professionals, and receive timely reminders, pharma brands can build lasting relationships beyond the initial prescription.
We’ve written about this before: Pfizer’s use of AI during the COVID-19 pandemic provides a strong example of how digital solutions can build trust and engagement. By using AI to optimise the production and delivery of PAXLOVID, patients received critical treatments faster. According to Pfizer, AI and ML (machine learning) was key:
“In one case, the cycle time of a critical step in the supply chain was able to be reduced by 67%, which enabled the production of 20,000 extra doses per batch.”
Operational efficiency is a concept that could be more exciting, but by delivering products and saving lives it’s an essential element of building brand loyalty and trust.
Digital transformation is critical
The evidence is clear: digital tools like the MedAire inflight app and Lunit's AI diagnostics are transforming healthcare delivery and outcomes.
Our team combines industry knowledge, best-in-breed technology intellectual property and practical methodologies to deliver real results to patients, doctors, prescribers, and sales professionals.
Ready to explore how digital transformation can drive results for your healthcare organisation? Get in touch or connect with us.
(1) Deloitte Global Health Care Sector Outlook
(2) Reducing the drug development timeline
Saving lives with fewer practitioners
These changes challenge how pharmaceutical brands engage patients and healthcare providers. Digital health platforms, mobile apps, and AI-driven solutions are not just opportunities for innovation—they are essential for staying competitive in a landscape where healthcare demand is outpacing traditional models.
And that’s just the commercial side. On the human, patient side, the opportunity for timely intervention and saving lives is compelling against a backdrop of steadily fewer practitioners in proportion to an ageing population.
What credentials do we have when writing about such topics? JOURNEY's leadership team has been working with Pharmaceutical and Medical Device companies for over 25 years, leading international change programmes in Europe, North America, and the Middle East.
Much change is happening even in a relatively technologically conservative industry like healthcare. Here are three ways digital trends drive significant change and outcomes for patients, healthcare providers, and pharma brands.
mHealth is changing everything
Digital health platforms fundamentally change how patients interact with healthcare providers and pharmaceutical companies. In the Asia Pacific region, mobile health apps (mHealth) are increasingly being adopted at a seemingly eye-watering speed, driven in part by the pandemic. In October 2020, a GMO study found that respondents from 30% (Japan) to 100% (Malaysia) reported using Health apps. Today, patients have many mHealth apps to track their health, access healthcare information, and communicate with providers.
This shift is creating a more personalised healthcare experience, improving adherence to treatment and engagement with healthcare systems.
AI and Personalisation: shaping patient care
AI in healthcare is becoming indispensable, particularly in personalised medicine. The global AI in Healthcare market size was valued at USD 20.9 billion in 2024 and is estimated to reach USD 148.4 billion by 2029, growing at a compound annual growth rate (CAGR) of 48.1% between 2024 and 2029, as patients and healthcare providers seek more tailored healthcare solutions.
AI-driven tools allow pharma companies to analyse patient data, predict health outcomes, and personalise treatment plans based on individual needs.
It’s strange to say about technology, but it’s hard to read about Lunit AI without feeling emotional. Based in South Korea, Lunit’s AI technology improves the accuracy of cancer diagnoses at a time when radiologists and associated services are under strain. The Cancer Registry of Norway and Odense University Hospital in Denmark just conducted a study and it found that Lunit AI predicts breast cancer risk up to 6 Years in advance, whilst reducing the workload of radiologists.
Build long term loyalty
Digital health tools help pharmaceutical brands reach new patients and create opportunities for long-term loyalty. A systematic review and meta-analysis by Peng et al. (2020) found that mobile apps significantly improved patient adherence to medication for chronic diseases. The same study reported that in those studies where user app acceptability was measured, 91.7% of patients were satisfied with all aspects of the apps.
By offering patients digital platforms to track their treatments, communicate with healthcare professionals, and receive timely reminders, pharma brands can build lasting relationships beyond the initial prescription.
We’ve written about this before: Pfizer’s use of AI during the COVID-19 pandemic provides a strong example of how digital solutions can build trust and engagement. By using AI to optimise the production and delivery of PAXLOVID, patients received critical treatments faster. According to Pfizer, AI and ML (machine learning) was key:
“In one case, the cycle time of a critical step in the supply chain was able to be reduced by 67%, which enabled the production of 20,000 extra doses per batch.”
Operational efficiency is a concept that could be more exciting, but by delivering products and saving lives it’s an essential element of building brand loyalty and trust.
Digital transformation is critical
The evidence is clear: digital tools like the MedAire inflight app and Lunit's AI diagnostics are transforming healthcare delivery and outcomes.
Our team combines industry knowledge, best-in-breed technology intellectual property and practical methodologies to deliver real results to patients, doctors, prescribers, and sales professionals.
Ready to explore how digital transformation can drive results for your healthcare organisation? Get in touch or connect with us.
(1) Deloitte Global Health Care Sector Outlook
(2) Reducing the drug development timeline
Saving lives with fewer practitioners
These changes challenge how pharmaceutical brands engage patients and healthcare providers. Digital health platforms, mobile apps, and AI-driven solutions are not just opportunities for innovation—they are essential for staying competitive in a landscape where healthcare demand is outpacing traditional models.
And that’s just the commercial side. On the human, patient side, the opportunity for timely intervention and saving lives is compelling against a backdrop of steadily fewer practitioners in proportion to an ageing population.
What credentials do we have when writing about such topics? JOURNEY's leadership team has been working with Pharmaceutical and Medical Device companies for over 25 years, leading international change programmes in Europe, North America, and the Middle East.
Much change is happening even in a relatively technologically conservative industry like healthcare. Here are three ways digital trends drive significant change and outcomes for patients, healthcare providers, and pharma brands.
mHealth is changing everything
Digital health platforms fundamentally change how patients interact with healthcare providers and pharmaceutical companies. In the Asia Pacific region, mobile health apps (mHealth) are increasingly being adopted at a seemingly eye-watering speed, driven in part by the pandemic. In October 2020, a GMO study found that respondents from 30% (Japan) to 100% (Malaysia) reported using Health apps. Today, patients have many mHealth apps to track their health, access healthcare information, and communicate with providers.
This shift is creating a more personalised healthcare experience, improving adherence to treatment and engagement with healthcare systems.
AI and Personalisation: shaping patient care
AI in healthcare is becoming indispensable, particularly in personalised medicine. The global AI in Healthcare market size was valued at USD 20.9 billion in 2024 and is estimated to reach USD 148.4 billion by 2029, growing at a compound annual growth rate (CAGR) of 48.1% between 2024 and 2029, as patients and healthcare providers seek more tailored healthcare solutions.
AI-driven tools allow pharma companies to analyse patient data, predict health outcomes, and personalise treatment plans based on individual needs.
It’s strange to say about technology, but it’s hard to read about Lunit AI without feeling emotional. Based in South Korea, Lunit’s AI technology improves the accuracy of cancer diagnoses at a time when radiologists and associated services are under strain. The Cancer Registry of Norway and Odense University Hospital in Denmark just conducted a study and it found that Lunit AI predicts breast cancer risk up to 6 Years in advance, whilst reducing the workload of radiologists.
Build long term loyalty
Digital health tools help pharmaceutical brands reach new patients and create opportunities for long-term loyalty. A systematic review and meta-analysis by Peng et al. (2020) found that mobile apps significantly improved patient adherence to medication for chronic diseases. The same study reported that in those studies where user app acceptability was measured, 91.7% of patients were satisfied with all aspects of the apps.
By offering patients digital platforms to track their treatments, communicate with healthcare professionals, and receive timely reminders, pharma brands can build lasting relationships beyond the initial prescription.
We’ve written about this before: Pfizer’s use of AI during the COVID-19 pandemic provides a strong example of how digital solutions can build trust and engagement. By using AI to optimise the production and delivery of PAXLOVID, patients received critical treatments faster. According to Pfizer, AI and ML (machine learning) was key:
“In one case, the cycle time of a critical step in the supply chain was able to be reduced by 67%, which enabled the production of 20,000 extra doses per batch.”
Operational efficiency is a concept that could be more exciting, but by delivering products and saving lives it’s an essential element of building brand loyalty and trust.
Digital transformation is critical
The evidence is clear: digital tools like the MedAire inflight app and Lunit's AI diagnostics are transforming healthcare delivery and outcomes.
Our team combines industry knowledge, best-in-breed technology intellectual property and practical methodologies to deliver real results to patients, doctors, prescribers, and sales professionals.
Ready to explore how digital transformation can drive results for your healthcare organisation? Get in touch or connect with us.
(1) Deloitte Global Health Care Sector Outlook
(2) Reducing the drug development timeline
